Lupus News

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

Twelve years is a long time by most measures, but in a field has rapidly changing as lupus nephritis research, it may as well be an eternity.

Depression and anxiety among patients with inflammatory arthritis is significantly undertreated, with large proportions not receiving minimally adequate care, according to data published in Arthritis Research & Therapy.

In this series, we dive into what rheumatologists should know about pulmonary hypertension, starting an interview with Joseph Parambil, MD, where we learn about the disease, when to suspect and how to work up!

MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.

The odds of developing systemic lupus erythematosus or systemic sclerosis appear to significantly increase with the use of menopausal hormone therapy, according to data published in Rheumatology.

Interferon-alpha activity may be used routinely in clinical settings as a biomarker for cutaneous lupus erythematosus and disease flares, according to a study.

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in Lupus Science & Medicine.

Exposure to various air pollutants, such as PM2.5 and nitrogen oxides, increases the risk for several autoimmune diseases, including psoriasis, lupus and rheumatoid arthritis, according to data published in Scientific Reports.